Menu
Search
|

Menu

Close
X

Verastem Inc VSTM.OQ (NASDAQ Stock Exchange Global Market)

5.11 USD
+0.32 (+6.68%)
As of Nov 15
chart
Previous Close 4.79
Open 4.82
Volume 507,248
3m Avg Volume 577,045
Today’s High 5.11
Today’s Low 4.72
52 Week High 10.34
52 Week Low 2.78
Shares Outstanding (mil) 73.74
Market Capitalization (mil) 373.13
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
26
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.008
FY17
-1.763
FY16
-0.985
FY15
-1.616
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
14.63
22.95
Price to Book (MRQ)
vs sector
3.47
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
23.29
15.47
LT Debt to Equity (MRQ)
vs sector
20.01
11.13
Return on Investment (TTM)
vs sector
-91.58
13.00
Return on Equity (TTM)
vs sector
-106.76
14.69

EXECUTIVE LEADERSHIP

Robert Forrester
President, Chief Executive Officer, Since 2014
Salary: $535,000.00
Bonus: --
Robert Gagnon
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Daniel Paterson
Chief Operating Officer, Since 2014
Salary: $363,058.00
Bonus: --
Joseph Lobacki
Executive Vice President and Chief Commercial Officer, Since 2018
Salary: --
Bonus: --
Joseph Chiapponi
Vice President - Finance, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

117 Kendrick St Ste 500
NEEDHAM   MA   02494-2730

Phone: +1781.2924200

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

SPONSORED STORIES